Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Gilead Sciences, Inc. Buenos Aires S.E.

Equities

GILD

ARBCOM4601C4

End-of-day quote Buenos Aires S.E.
Other stock markets
 23:00:00 24/06/2024 BST 		5-day change 1st Jan Change
22,806 ARS -2.12% Intraday chart for Gilead Sciences, Inc. +14.65% +15.36%
12:51pm Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117 MT
06-25 IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer CI

Evolution of the average Target Price on Gilead Sciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4be1eacced81b7.TaNGsBiRjRqlr4GS3ZF3UC_6QC2yRqDei7XGeZ_0cBw.Ifo8wnnE3WLt1evZmtokIRqweFTqDJes6oSUDqquMVMDlQGdbvrMVe3XtQ~573a47072d6ee4e8af3664cea26a6630

Analyst Recommendations on Gilead Sciences, Inc.

Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117 MT
Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80 MT
UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating MT
Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 MT
Maxim Adjusts Price Target on Gilead Sciences to $85 From $90 MT
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $117 From $120 MT
Barclays Adjusts Price Target on Gilead Sciences to $76 From $80 MT
TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 MT
Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 MT
RBC Capital Adjusts Gilead Sciences' Price Target to $74 From $76 MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80 MT
North American Morning Briefing : More Tech -2- DJ
HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69 MT
Argus Cuts Price Target on Gilead Sciences to $75 From $85 MT
Cantor Fitzgerald Adjusts Gilead Sciences' Price Target to $75 From $78, Maintains Neutral Rating MT
BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89 MT
Leerink Partners Adjusts Gilead Sciences Price Target to $74 From $79 MT
UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating MT
Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76 MT
Morgan Stanley Cuts Price Target on Gilead Sciences to $80 From $83, Keeps Equalweight Rating MT
Wells Fargo Cuts Price Target on Gilead Sciences to $78 From $84, Keeps Equalweight Rating MT
Mizuho Securities Cuts Price Target on Gilead Sciences to $90 From $101, Maintains Buy Rating MT
Truist Securities Downgrades Gilead Sciences to Hold From Buy, Cuts Price Target to $82 From $91 MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia... Our Logo
RBC Trims Price Target on Gilead Sciences to $75 From $76, Keeps Sector Perform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.61 USD
Average target price
82.97 USD
Spread / Average Target
+19.19%
High Price Target
119 USD
Spread / Highest target
+70.95%
Low Price Target
67 USD
Spread / Lowest Target
-3.75%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Gilead Sciences, Inc.

UBS
Deutsche Bank Securities
Maxim
Redburn Atlantic
Barclays
TD Cowen
Jefferies & Co.
RBC Capital Markets
Morgan Stanley
HSBC
Argus
Cantor Fitzgerald
BMO Capital
Leerink Partners
Goldman Sachs
Wells Fargo Securities
Mizuho Securities
Truist Securities
Oppenheimer
Piper Sandler
BofA Securities
SVB Securities LLC
Cowen
JPMorgan Chase
SVB Leerink
Credit Suisse
Bernstein
Redburn
DZ BANK Elmar Kraus

Ratings for Gilead Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. GILD Stock
  5. Consensus Gilead Sciences, Inc.